Kazakh Cerebra AI has signed a contract with an American medical group with revenues exceeding $20 billion

Kazakh startup Cerebra AI, developing artificial intelligence-based solutions for early stroke detection, has announced the signing of a long-term contract with a major strategic partner in the United States—a medical group with over 150 years of history and annual revenue exceeding $20 billion. The terms of the agreement are not disclosed due to an NDA.

Working with Cerebra AI, we discovered another path: a small, local, and fully explainable model, placed correctly within a clinical protocol, already delivers significant improvements in diagnosis and clinical medicine today. Essentially, what LLMs promise for the future, we are achieving today, and with much greater energy efficiency and safety. This is not a hypothesis—we have proven it with stroke. And now, major players in the global healthcare market have taken notice, and this partnership is proof.

The partnership is set for five years. As part of the deal, the partner will invest resources into expanding the functionality of the Cerebra AI platform beyond stroke detection to include the identification of cardiovascular diseases and various types of cancer.

Simultaneously, the company is progressing toward obtaining medical certification in the United States: two stages of the process have already been completed, and only one clinical trial remains to be conducted for the approval of the first feature. The certification application is planned to be submitted in 2027.

The partnership continues a series of successes for Cerebra AI in the international market. The company was recognized as one of the top 5 AI laboratories in the world in the field of neuroscience by StartUs, an Austrian analytics agency, as well as the best AI project in the MedTech sector within the HealthUnity medical community at Stanford University. The team also took first place in the AI Olympiad in the United States, organized by Intel Corporation.

One of the company's first and ongoing investors is Timur Turlov, head of Freedom Holding, who supported the idea of creating advanced medical technologies in Kazakhstan.